Generic Name and Formulations:
Pyridostigmine bromide 5mg/mL; soln for IV inj; contains benzyl alcohol.
Indications for REGONOL:
As a reversal agent or antagonist to the neuromuscular blocking effects of nondepolarizing muscle relaxants.
Individualize. Give by IV inj. Usual range: 0.1–0.25mg/kg. Give atropine sulfate or equipotent dose of glycopyrrolate immediately prior to or simultaneously with Regonol.
Intestinal or urinary obstruction.
Bronchial asthma. Cardiac dysrhythmias. Electrolyte imbalance. Adrenal cortical insufficiency. Renal impairment. Neonates. Pregnancy (Cat.C).
Concomitant 4-aminopyridine may delay onset. Possible resistance to reversal with antibiotics associated with paralysis (eg, aminoglycosides, tetracyclines, bacitracin, polymyxin B, colistin, sodium colistimethate). Recurrent paralysis possible with quinidine. Magnesium salts may enhance neuromuscular blockade and interfere with restoration.
GI upset, increased salivation and bronchial secretions, miosis and diaphoresis, muscle cramps, fasciculation and weakness, rash.